Real-World Tirzepatide Therapy in Post-Bariatric Weight Regain and Preoperative Obesity Patients

nclusion Criteria * Adult patients aged 18 years or older. * Diagnosis of obesity, defined according to standard clinical criteria, managed within a bariatric and metabolic care pathway. * Initiation of tirzepatide therapy at a starting dose of 5 mg as part of routine clinical practice. * Allocation to one of the following clinical cohorts: * Patients with prior sleeve gastrectomy and clinically significant weight regain, defined as a ≥25% increase in body weight relative to the postoperative nadir weight, with a minimum interval of 36 months from surgery; or * Patients with obesity undergoing preoperative medical optimization prior to planned bariatric surgery. * Availability of complete baseline clinical and anthropometric data at treatment initiation. * Planned clinical follow-up for at least 6 months after initiation of tirzepatide therapy. * Ability to provide written informed consent for the use of clinical data for research purposes, according to local regulations. Exclusion Criteria * Age younger than 18 years. * Prior bariatric procedures other than sleeve gastrectomy (for the weight regain cohort). * Current or previous treatment with tirzepatide before study enrollment. * Use of other anti-obesity pharmacological agents during the observation period. * Contraindications to tirzepatide therapy according to the approved product label. * Pregnancy or breastfeeding at the time of treatment initiation or during follow-up. * Presence of severe medical, psychiatric, or…